Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-03-13
1999-05-11
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 9, 514 11, A61K38/05
Patent
active
059027908
ABSTRACT:
Disclosed are methods of inhibiting neovascularization in a subject by administering to the subject a pharmaceutical preparation of R'-Glu-Trp-R".
REFERENCES:
patent: 4191753 (1980-03-01), Ryan
patent: 5100873 (1992-03-01), de Castiglione et al.
patent: 5538951 (1996-07-01), Morozov et al.
patent: 5728680 (1998-03-01), Morozov et al.
patent: 5767087 (1998-06-01), Morozov et al.
patent: 5770576 (1998-06-01), Morozov et al.
Rodionov et al. (1990) "The Immunocorrective Therapy of Pyoderma Caused by Staphylococci Multiply Resistant to Antibiotics", Vestn. Dermatol. Venerol, 1:42-45 (Medline Abstract No. 90224329).
J. Folkman (1990) J. Natl. Cancer Inst. 82:4-6. What Is the Evidence That Tumors ARe Angiogenesis Dependent?.
S. Nakamura et al. (1988) Science 242:426-430. Kaposi's Sarcoma Cells: Long-Term Culture with Growth Factor from Retrovirus-Infected CD4+ T Cells.
T.E. Maione et al. (1990) Trends in Pharmaceutical Sciences 11:457-461. Development of angiogenesis inhibitors for clinical applications.
R.L. Heimark (1986) Science 233:1078-1080. Inhibition of Endothelial Regeneration by Type-Beta Transforming Growth Factor from Platelets.
Frater-Schroder et al. (1987) Proc. Natl. Acad. Sci. USA 84:5277-5281. Tumor necrosis factor type .alpha., a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo.
Y.A. Sidky et al. (1987) Cancer Res. 47:5155-5161. Inhibition of Angiogenesis by Interferons: Effects on Tumor- and Lymphocyte-induced Vascular Responses.
D.M. Wiseman et al. (1988) Biophys. Res. Commun. 157:793-800. Transforming Growth Factor-Beta (TGF.beta.) Is Chemotactic For Human Monocytes And Induces Their Expression Of Angiogenic Activity.
J.O. Kahn et al. (1989) J. Aids 2:217-223. Intralesional Recombinant Tumor Necrosis Factor-.alpha. for AIDS-Associated Kaposi's Sarcoma: A Randomized, Double-Blind Trial.
T.E. Maione (1995) IBC Conference "Chemotactic Cytokines" Oct. 26, 1995. Direct Clinical Applications of Chemokines.
D. Knighton et al. (1977) J. Cancer 35:347-335. Avascular And Vascular Phases Of Tumour Growht In The Chick Embryo.
Database WPI, Section Ch, Week 9501, Derwent Publications Ltd., London, GB; Class B05, An 95-004962, XP002023100, & SU, A, 1 827 255 (Kiev Doctor Training Inst), Jul. 15, 1993. Abstract only.
Database WPI, Section Ch, Week 9212, Derwent Publications Ltd. London, GB; Class B04, AN 92-94519, XP002023101 & SU, A, 1 642 398 (Rost Med Inst), Apr. 15, 1991. Abstract only.
Database WPI, Section Ch, Week 9511, Derwent Publications Ltd. London, GB; Class B05, AN 95-080267, XP 002023102 & RU, C, 2 014 063 (Sochi Spas Physiotherapy Res Inst), Jun. 15, 1994. Abstract only.
Blasecki John W.
Green Lawrence R.
Celsa Bennett
Cytran, Inc.
Tsang Cecilia J.
LandOfFree
Pharmaceutical angiostatic dipeptide compositions and method of does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical angiostatic dipeptide compositions and method of , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical angiostatic dipeptide compositions and method of will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-245632